Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892973 | 0.85 | ELANE (0.43) | CNR2HTR7PTGER2PTGER3POLB | |
| SCHEMBL6996087 | 0.80 | HDAC1 (0.41) | HDAC1HDAC8HDAC6PTGER2PTGER3 | |
| SCHEMBL16422721 | 0.80 | HDAC1 (0.49) | CNR2HDAC1HDAC8HDAC6HTR7 | |
| SCHEMBL18013330 | 0.80 | HDAC1 (0.44) | CNR2HDAC1HDAC8HDAC6PTGER2 | |
| SCHEMBL16423061 | 0.80 | HDAC1 (0.49) | CNR2HDAC1HDAC8HDAC6HTR7 | |
| SCHEMBL16422722 | 0.80 | HDAC1 (0.49) | CNR2HDAC1HDAC8HDAC6HTR7 | |
| SCHEMBL16096237 | 0.80 | PTGER2 (0.44) | HDAC1HDAC8HDAC6PTGER2PTGER3 | |
| SCHEMBL17501926 | 0.80 | PTGER2 (0.44) | HDAC1HDAC8HDAC6PTGER2PTGER3 | |
| SCHEMBL19745517 | 0.79 | HDAC1 (0.52) | HDAC1HDAC8HDAC6 | |
| SCHEMBL19745519 | 0.79 | HDAC1 (0.52) | HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | CNR2 6/4885HDAC1 933/4885HDAC8 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.